ES3062435T3 - Solid extended-release composition comprising bradykinin b2-receptor antagonists - Google Patents
Solid extended-release composition comprising bradykinin b2-receptor antagonistsInfo
- Publication number
- ES3062435T3 ES3062435T3 ES23715488T ES23715488T ES3062435T3 ES 3062435 T3 ES3062435 T3 ES 3062435T3 ES 23715488 T ES23715488 T ES 23715488T ES 23715488 T ES23715488 T ES 23715488T ES 3062435 T3 ES3062435 T3 ES 3062435T3
- Authority
- ES
- Spain
- Prior art keywords
- approximately
- tablet
- matrix
- disease
- matrix tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22164471 | 2022-03-25 | ||
| PCT/EP2023/057792 WO2023180576A1 (en) | 2022-03-25 | 2023-03-27 | Solid extended-release composition comprising bradykinin b2-receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3062435T3 true ES3062435T3 (en) | 2026-04-10 |
Family
ID=80952430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES23715488T Active ES3062435T3 (en) | 2022-03-25 | 2023-03-27 | Solid extended-release composition comprising bradykinin b2-receptor antagonists |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20250228782A1 (enExample) |
| EP (2) | EP4499039B1 (enExample) |
| JP (1) | JP2025510860A (enExample) |
| KR (1) | KR20240161195A (enExample) |
| CN (1) | CN119136786A (enExample) |
| AU (1) | AU2023240388A1 (enExample) |
| CA (1) | CA3250834A1 (enExample) |
| CO (1) | CO2024012885A2 (enExample) |
| DK (1) | DK4499039T3 (enExample) |
| ES (1) | ES3062435T3 (enExample) |
| FI (1) | FI4499039T3 (enExample) |
| HR (1) | HRP20260203T1 (enExample) |
| IL (1) | IL315700A (enExample) |
| LT (1) | LT4499039T (enExample) |
| MA (1) | MA69210B1 (enExample) |
| MX (1) | MX2024011704A (enExample) |
| PL (1) | PL4499039T3 (enExample) |
| PT (1) | PT4499039T (enExample) |
| RS (1) | RS67776B1 (enExample) |
| SI (1) | SI4499039T1 (enExample) |
| SM (1) | SMT202600057T1 (enExample) |
| TW (1) | TW202345810A (enExample) |
| WO (1) | WO2023180576A1 (enExample) |
| ZA (1) | ZA202408059B (enExample) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1168667A (zh) | 1994-10-27 | 1997-12-24 | 藤沢药品工业株式会社 | 用作缓激肽拮抗剂的吡啶并嘧啶酮，喹啉和稠合的n-杂环化合物 |
| FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
| DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| AUPN952696A0 (en) | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| EP1085895A1 (en) | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Bradykinin antagonists |
| EP1123288A1 (en) | 1998-10-21 | 2001-08-16 | Fujisawa Pharmaceutical Co., Ltd. | Vitreous form of known bradykinin antagonist |
| FR2790260B1 (fr) | 1999-02-26 | 2001-05-04 | Fournier Ind & Sante | Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique |
| CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| JP2005525398A (ja) | 2002-04-10 | 2005-08-25 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体 |
| ITMI20021247A1 (it) | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
| TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| KR20150127718A (ko) | 2013-03-14 | 2015-11-17 | 샤이어 휴먼 지네틱 테라피즈 인크. | Ｂ2-브라디키닌 수용체 매개 혈관부종의 치료 방법 |
| SMT202200154T1 (it) * | 2017-11-24 | 2022-05-12 | Pharvaris Netherlands B V | Nuovi antagonisti del recettore della bradichinina b2 |
| AR118983A1 (es) * | 2019-05-23 | 2021-11-17 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
| CA3198246A1 (en) * | 2020-11-12 | 2022-05-19 | Pharvaris Gmbh | Prophylaxis and treatment of angioedema |
-
2023
- 2023-03-25 TW TW112111337A patent/TW202345810A/zh unknown
- 2023-03-27 PL PL23715488.5T patent/PL4499039T3/pl unknown
- 2023-03-27 EP EP23715488.5A patent/EP4499039B1/en active Active
- 2023-03-27 CN CN202380037796.5A patent/CN119136786A/zh active Pending
- 2023-03-27 AU AU2023240388A patent/AU2023240388A1/en active Pending
- 2023-03-27 SM SM20260057T patent/SMT202600057T1/it unknown
- 2023-03-27 WO PCT/EP2023/057792 patent/WO2023180576A1/en not_active Ceased
- 2023-03-27 ES ES23715488T patent/ES3062435T3/es active Active
- 2023-03-27 MA MA69210A patent/MA69210B1/fr unknown
- 2023-03-27 RS RS20260209A patent/RS67776B1/sr unknown
- 2023-03-27 US US18/850,683 patent/US20250228782A1/en active Pending
- 2023-03-27 EP EP25219557.3A patent/EP4684830A3/en active Pending
- 2023-03-27 SI SI202330074T patent/SI4499039T1/sl unknown
- 2023-03-27 HR HRP20260203TT patent/HRP20260203T1/hr unknown
- 2023-03-27 JP JP2024556788A patent/JP2025510860A/ja active Pending
- 2023-03-27 DK DK23715488.5T patent/DK4499039T3/da active
- 2023-03-27 LT LTEPPCT/EP2023/057792T patent/LT4499039T/lt unknown
- 2023-03-27 FI FIEP23715488.5T patent/FI4499039T3/fi active
- 2023-03-27 KR KR1020247035307A patent/KR20240161195A/ko active Pending
- 2023-03-27 IL IL315700A patent/IL315700A/en unknown
- 2023-03-27 CA CA3250834A patent/CA3250834A1/en active Pending
- 2023-03-27 PT PT237154885T patent/PT4499039T/pt unknown
-
2024
- 2024-09-24 MX MX2024011704A patent/MX2024011704A/es unknown
- 2024-09-24 CO CONC2024/0012885A patent/CO2024012885A2/es unknown
- 2024-10-24 ZA ZA2024/08059A patent/ZA202408059B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20250228782A1 (en) | 2025-07-17 |
| SI4499039T1 (sl) | 2026-04-30 |
| IL315700A (en) | 2024-11-01 |
| LT4499039T (lt) | 2026-02-25 |
| AU2023240388A1 (en) | 2024-11-07 |
| PT4499039T (pt) | 2026-02-17 |
| MA69210B1 (fr) | 2026-02-27 |
| CO2024012885A2 (es) | 2024-10-10 |
| PL4499039T3 (pl) | 2026-03-30 |
| TW202345810A (zh) | 2023-12-01 |
| FI4499039T3 (fi) | 2026-02-05 |
| MX2024011704A (es) | 2024-11-08 |
| JP2025510860A (ja) | 2025-04-15 |
| EP4499039B1 (en) | 2025-12-03 |
| CN119136786A (zh) | 2024-12-13 |
| ZA202408059B (en) | 2026-01-28 |
| SMT202600057T1 (it) | 2026-03-09 |
| HRP20260203T1 (hr) | 2026-03-27 |
| EP4499039A1 (en) | 2025-02-05 |
| DK4499039T3 (da) | 2026-02-16 |
| EP4684830A2 (en) | 2026-01-28 |
| CA3250834A1 (en) | 2023-09-28 |
| KR20240161195A (ko) | 2024-11-12 |
| WO2023180576A1 (en) | 2023-09-28 |
| EP4684830A3 (en) | 2026-04-01 |
| RS67776B1 (sr) | 2026-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2993251T3 (en) | Pharmaceutical compositions of nilotinib | |
| CA2700426C (en) | Compositions comprising lipophilic active compounds and method for their preparation | |
| CN101636152B (zh) | 含有西洛他唑的控释制剂及其制备方法 | |
| CN103998037B (zh) | 对高熔点疏水性化合物具有改进的生物利用度的药物组合物 | |
| ES3018265T3 (en) | Orally administrable enzalutamide-containing pharmaceutical composition | |
| KR20150082203A (ko) | 엔잘루타마이드 제제 | |
| CN104936589A (zh) | 具有改善的生物利用度的药物组合物 | |
| CN115916160A (zh) | Malt1抑制剂的无定形形式及其制剂 | |
| AU2016372683A1 (en) | Complexes of celecoxib and its salts and derivatives process for the preparation thereof and pharmaceutical compositions containing them | |
| ES3062067T3 (en) | Solid composition comprising solubilised bradykinin b2-receptor antagonists | |
| EP4499039B1 (en) | Solid extended-release composition comprising bradykinin b2-receptor antagonists | |
| CN110035756A (zh) | 含有他达拉非的药物配制品 | |
| US20250268887A1 (en) | Therapeutic uses of bradykinin b2-receptor antagonists | |
| EA052832B1 (ru) | Твердая композиция с пролонгированным высвобождением, содержащая антагонисты брадикининовых в2-рецепторов | |
| EP3764983B1 (en) | A sustained release formulation comprising acemetacin with bimodal in vitro release | |
| JP2026508635A (ja) | ダニコパンの製剤及びその使用方法 | |
| CN120076794A (zh) | 包含纳波拉非尼的无定形固体分散体 | |
| WO2024214120A1 (en) | Pharmaceutical compositions of nilotinib | |
| CN118526459A (zh) | 一种达罗他胺固分体及其制备方法 |